Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alteon (ALT) -- Ignore unavailable to you. Want to Upgrade?

To: Jonathan Rothschild who wrote (177)	12/7/1997 11:47:00 AM
From: Rudy Saucillo	Respond to of 318

Well, the private financing was necessary and done with absolute minimum dilution. This is what I meant previously when I said 'hats off to Mauzey for preserving shareholder value.' I had expected a series of private rounds totaling $12-$15 million. I couldn't be more pleased with ALTN's business management. The toxicities associated with aminoguanidine are well understood and ALTN has methods to deal with the early flu-like symptoms. There are no other tox issues that I'm aware of. Snobbish management??? I'm not sure what you mean, but their senior management, board of directors, and SAB are top notch and have been extremely effective on both the technical and business ends. I'm a very happy shareholder. ALTN got what they wanted in their partnership, and it came sooner than I had anticipated. Rudy